Format
Sort by
Items per page

Send to

Choose Destination

Best matches for alcoholic intoxication, chronic AND analgesics, opioid AND naltrexone AND substance abuse problem:

Search results

Items: 1 to 20 of 47

1.

Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.

Franchitto N, Jullian B, Salles J, Pelissier F, Rolland B.

Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):669-677. doi: 10.1080/17425255.2017.1312340. Epub 2017 Apr 3. Review.

PMID:
28343423
2.

Functional modulation on macrophage by low dose naltrexone (LDN).

Yi Z, Guo S, Hu X, Wang X, Zhang X, Griffin N, Shan F.

Int Immunopharmacol. 2016 Oct;39:397-402. doi: 10.1016/j.intimp.2016.08.015. Epub 2016 Aug 23.

PMID:
27561742
3.

Pharmacotherapy for Substance Use Disorders.

Klein JW.

Med Clin North Am. 2016 Jul;100(4):891-910. doi: 10.1016/j.mcna.2016.03.011. Epub 2016 Apr 20. Review.

PMID:
27235620
4.

Neuroimaging the Effectiveness of Substance Use Disorder Treatments.

Cabrera EA, Wiers CE, Lindgren E, Miller G, Volkow ND, Wang GJ.

J Neuroimmune Pharmacol. 2016 Sep;11(3):408-33. doi: 10.1007/s11481-016-9680-y. Epub 2016 May 16. Review.

PMID:
27184387
5.

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.

Berrettini W.

Prog Brain Res. 2016;223:253-67. doi: 10.1016/bs.pbr.2015.07.030. Epub 2015 Oct 21. Review.

PMID:
26806780
6.

[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].

Dahmke H, Kupferschmidt H, Kullak-Ublick GA, Weiler S.

Praxis (Bern 1994). 2015 Oct 14;104(21):1129-34. doi: 10.1024/1661-8157/a002160. German.

7.

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.

Ripley TL, Sanchez-Roige S, Bullmore ET, Mugnaini M, Maltby K, Miller SR, Wille DR, Nathan P, Stephens DN.

Psychopharmacology (Berl). 2015 Sep;232(18):3431-41. doi: 10.1007/s00213-015-3995-x. Epub 2015 Jul 5.

8.

Severe opioid withdrawal syndrome after a single dose of nalmefene.

Donnerstag N, Schneider T, Lüthi A, Taegtmeyer A, Raetz Bravo A, Mehlig A.

Eur J Clin Pharmacol. 2015 Aug;71(8):1025-6. doi: 10.1007/s00228-015-1884-1. Epub 2015 Jun 7. No abstract available.

PMID:
26050241
9.

Informed consent abandoned--patient given contraindicated drug.

Gregg M, Martinez L, Samaritan G.

J Med Assoc Ga. 2014;103(2):22. No abstract available.

PMID:
25185350
10.

Protracted withdrawal from ethanol and enhanced responsiveness stress: regulation via the dynorphin/kappa opioid receptor system.

Gillett K, Harshberger E, Valdez GR.

Alcohol. 2013 Aug;47(5):359-65. doi: 10.1016/j.alcohol.2013.05.001. Epub 2013 May 31.

11.

Medications for substance use disorders.

Douaihy AB, Kelly TM, Sullivan C.

Soc Work Public Health. 2013;28(3-4):264-78. doi: 10.1080/19371918.2013.759031. Review.

12.

κ opioid regulation of anxiety-like behavior during acute ethanol withdrawal.

Valdez GR, Harshberger E.

Pharmacol Biochem Behav. 2012 Jul;102(1):44-7. doi: 10.1016/j.pbb.2012.03.019. Epub 2012 Apr 2.

13.

Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects.

Weerts EM, McCaul ME, Kuwabara H, Yang X, Xu X, Dannals RF, Frost JJ, Wong DF, Wand GS.

Int J Neuropsychopharmacol. 2013 Feb;16(1):47-53. doi: 10.1017/S146114571200017X. Epub 2012 Mar 8.

PMID:
22397905
14.

Interaction between family history of alcoholism and Locus of Control in the opioid regulation of impulsive responding under the influence of alcohol.

Altamirano LJ, Fields HL, D'Esposito M, Boettiger CA.

Alcohol Clin Exp Res. 2011 Nov;35(11):1905-14. doi: 10.1111/j.1530-0277.2011.01535.x. Epub 2011 May 13.

15.

Drug treatment as HIV prevention: expanding treatment options.

Metzger DS, Zhang Y.

Curr HIV/AIDS Rep. 2010 Nov;7(4):220-5. doi: 10.1007/s11904-010-0059-z. Review.

16.

Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety.

van Rijn RM, Brissett DI, Whistler JL.

J Pharmacol Exp Ther. 2010 Oct;335(1):133-9. doi: 10.1124/jpet.110.170969. Epub 2010 Jul 6.

17.

The implications of medication development in the treatment of substance use disorders in developing countries.

Thirthalli J, Chand PK.

Curr Opin Psychiatry. 2009 May;22(3):274-80. doi: 10.1097/YCO.0b013e32832a1dc0. Review.

PMID:
19346946
18.

Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.

Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):345-9. doi: 10.1016/j.drugalcdep.2008.07.018. Epub 2008 Sep 25.

19.

Pharmacogenetic treatments for drug addiction: alcohol and opiates.

Haile CN, Kosten TA, Kosten TR.

Am J Drug Alcohol Abuse. 2008;34(4):355-81. doi: 10.1080/00952990802122564. Review.

PMID:
18584566
20.

Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone.

Dean RL, Todtenkopf MS, Deaver DR, Arastu MF, Dong N, Reitano K, O'Driscoll K, Kriksciukaite K, Gastfriend DR.

Pharmacol Biochem Behav. 2008 Jun;89(4):515-22. doi: 10.1016/j.pbb.2008.02.006. Epub 2008 Feb 11.

PMID:
18342360

Supplemental Content

Loading ...
Support Center